StocksMediumUpdated×3•Originally published 4 November 2026•Updated 4 November 2026•
1 min read
United Therapeutics Buys Out Ralinepag Royalty Obligations for $525M Amid Q3 Results
Key Facts
1United Therapeutics reported total revenues of $832.5 million for the third quarter of 2026, a four percent increase year-over-year.
United Therapeutics announced a $525 million payment to Arena Pharmaceuticals, a subsidiary of Pfizer, to eliminate all royalty obligations related to ralinepag. The announcement came as the company reported third-quarter revenue of $832.5 million, exceeding analyst expectations of $782.6 million.
Business Wire reported that the company posted GAAP earnings per share of $5.71, missing analyst estimates by $0.33 for the period ended September 30, 2026. UTHR closed at $601.32 on November 3, 2026, after reaching a session high of $606.72.